Introduction {#s1}
============

Acetylcholine (Ach) effects are mediated via metabotropic G-protein coupled muscarinic receptors (mAchRs) and ionotropic nicotinic receptors (nAchRs). They are important for cognitive functions such as working, episodic and spatial memory, or attention (Hefco et al., [@B49]; Newman et al., [@B89]). In the striatum (caudate-putamen, CPu), complex bidirectional interactions of the cholinergic and dopaminergic systems are fundamental for normal functioning (Calabresi et al., [@B21]; Cragg, [@B27]; Goldberg et al., [@B43]). Both nAchRs (Giorguieff et al., [@B41]; Rapier et al., [@B99]; Grady et al., [@B44]; El-Bizri and Clarke, [@B39]; Sharples et al., [@B105]; Wonnacott et al., [@B122]; Zhou et al., [@B132]) and mAchRs (Westfall, [@B121]; Zhang et al., [@B131]; Zhang and Sulzer, [@B130]; Threlfell et al., [@B112]) modulate dopamine (DA) release from synaptic terminals.

The nAChRs (such as the α~4~β~2~ subtype) as well as mAChRs (M~1~-M~5~ subtypes) interact in a complex manner to modulate synaptic plasticity in the striatum. M~1~ receptors presynaptically located on medium spiny neurons (MSNs) inhibit GABA release (Sugita et al., [@B109]). To a lesser degree, glutamate release from glutamatergic terminals is also inhibited by activation of other muscarinic presynaptic receptors. Since the effect on GABA release dominates, the netto effect of M~1~ receptor activation is increased excitability (Sugita et al., [@B109]). M~2~ and M~3~ receptors both regulate glutamatergic release from cortical nerve terminals (Calabresi et al., [@B20]; Pakhotin and Bracci, [@B91]). Activation of M~4~ receptors, which often form heterodimers with the excitatory D~1~ receptor on MSNs (Ince et al., [@B57]) results in the inhibition of these neurons. Presynaptic M~2~ and M~4~ receptors modulate glutamate release from corticostriatal afferents and GABA release from GABAergic interneurons (Benarroch, [@B12]). Moreover, M~2~ and M~4~ receptors were both found as autoreceptors on cholinergic interneurons in the striatum (Zhou et al., [@B133]). Also nAChRs are expressed on cholinergic interneurons as well as on corticostriatal and nigrostriatal terminals. They modulate glutamate release (Zhou et al., [@B133]). However, the precise functions of nAChRs and mAChRs subtypes are still subject of ongoing research.

In Parkinson\'s disease (PD) the primary neuropathological characteristic is the dopaminergic denervation of the CPu caused by progressive dopaminergic cell death in the substantia nigra pars compacta (SNpc) (Hornykiewicz, [@B52]; Bernheimer et al., [@B15]). The resulting DA deficit triggers its cardinal clinical symptoms including tremor, rigidity, bradykinesia and postural instability (Cutson et al., [@B31]). Further, the absent inhibition of tonically active cholinergic interneurons by DA results in relative hypercholinism (Spehlmann and Stahl, [@B107]; Aosaki et al., [@B4]), which additionally worsens the pathological motor manifestations (Marti et al., [@B78]; Pisani et al., [@B94]; Ding et al., [@B36]). Consequently, disturbances in cholinergic neurotransmission are associated with symptoms of PD (Lester et al., [@B70]).

Symptomatic pharmacological treatments of PD are DA replacement therapy with L-Dopa (Carlsson et al., [@B23]; Duvoisin, [@B38]; Volpato et al., [@B118]), administration of DA receptor agonists, of catecholamine-O-methyl transferase inhibitors, and of anticholinergics drugs including mAchR antagonists (Horstink et al., [@B53],[@B54]; Langmead et al., [@B68]). Anticholinergic substances have anti-parkinsonian effects on motor dysfunction (Brooks, [@B19]; Lees, [@B69]). The systemic administration of anticholinergica is, however, accompanied by massive side effects (Katzenschlager and Lees, [@B62]; Fernandez, [@B40]). We recently demonstrated that the local injection of the anticholinergic Botulinum neurotoxin-A (BoNT-A) into the CPu is a potent new experimental therapy in 6-hydroxdopamine (6-OHDA)-induced hemiparkinsonian (hemi-PD) rats. Peripheral and central side effects of systemically applied anticholinergica are avoided in this approach (Wree et al., [@B125]; Antipova et al., [@B3]; Wedekind et al., [@B120]).

Experimental animal models that mimic aspects of PD by destruction of the nigrostriatal pathway are frequently used in PD\'s research and therapy testing. One is the hemi-PD rat model, which is generated by unilateral stereotaxic injection of the neurotoxin 6-OHDA into the medial forebrain bundle (MFB) (Ungerstedt, [@B114]; Ungerstedt and Arbuthnott, [@B115]; Schwarting and Huston, [@B102]; Blandini et al., [@B17]; Duty and Jenner, [@B37]; Tieu, [@B113]). The resulting dopaminergic depletion in hemi-PD rats affects motor behavior as seen in the apomorphine-induced rotation test (Ungerstedt et al., [@B116]). We previously demonstrated that apomorphine-induced contralateral rotations of hemi-PD rats are abolished by ipsilateral injection of BoNT-A up to 6 months (Wree et al., [@B125]; Antipova et al., [@B3], [@B2]; Mann et al., [@B76],[@B77]). Moreover, BoNT-A does not have cytotoxic effects in the rat brain (Mehlan et al., [@B82]), and does not impair cognition but reduces anxiety in naïve rats (Holzmann et al., [@B51]). BoNT-A inhibits Ach release from presynaptic terminals by cleavage of the synaptosome-associated glycoprotein of 25-kDa (SNAP25), and thus prevents cholinergic hyperactivity (Coffield et al., [@B26]; Caleo et al., [@B22]). However, the molecular and cellular mechanisms of the observed behavioral effects of BoNT-A on hemi-PD rats have not yet been fully examined.

To explore the role of cholinergic receptors and its changes after DA deprivation and following BoNT-A injection, we comprehensively examined striatal receptor densities of mAchRs (M~1~, M~2~, M~3~, M~4~ subtypes) and nAchRs (α~4~β~2~ subtype) up to a survival time of 9 months using quantitative *in vitro* receptor autoradiography. First, we analyzed time-dependent changes in receptor densities in 6-OHDA-induced hemi-PD rats relative to controls. Then the long-term effects of intrastriatal BoNT-A injections in naïve rats were investigated. To our knowledge, this is the first study analyzing long-term effects of 6-OHDA and intrastriatal BoNT-A injections.

Materials and methods {#s2}
=====================

Animals
-------

One hundred and twenty-eight male Wistar rats (strain Crl:WI BR) aged 3 months and weighing 250--280 g were obtained from Charles River WIGA (Sulzfeld, Germany). Animals were housed in a temperature-controlled room (22 ± 2°C) under a fixed 12 h light/12 h dark cycle and had free access to food and water 24 h a day. Animal treatment was in line with legal obligations of the animal welfare act and all animal experiments were approved by the state Animal Research Committee of Mecklenburg-Western Pomerania (LALLF M-V/TSD/7221.3-1.1-003/13).

Stereotactic interventions
--------------------------

Anesthesia was performed via intraperitoneal (i.p.) injection of a mixture of ketamine (50 mg/kg body weight) and xylazine (4 mg/kg body weight). Rats were operated under aseptic conditions at a weight of 285--305 g. Animals were fixed in a rat stereotactic apparatus (Kopf, Tujunga, CA, USA) and 6-OHDA solution was injected evenly over 4 min via a 26 gauge 5 μl Hamilton syringe into the right MFB. The coordinates of the 6-OHDA injection with reference to bregma were: anterior-posterior = −2.3 mm, lateral = −1.5 mm and ventral = −9.0 mm (Paxinos and Watson, [@B92]). Hemi-PD was induced by the unilateral injection of 4 μl of 6-OHDA (24 μg) (Sigma-Aldrich, St. Louis, MO) dissolved in 0.1 M citrate buffer. Application of BoNT-A (lot No. 13028A1A; List, Campbell, CA; purchased via Quadratech, Surrey, UK) or of vehicle was carried out 6 weeks after 6-OHDA lesion. BoNT-A was handled and stored according to the precautions given by the manufacturer. The coordinates of the two BoNT-A or vehicle injections with reference to bregma were: anterior-posterior = +1.3 mm/−0.4 mm, lateral = −2.6 mm/−3.6 mm and ventral = −5.5 mm/−5.5 mm (right CPu) (Paxinos and Watson, [@B92]). For details of the different control and experimental groups see Table [1](#T1){ref-type="table"}.

###### 

Details of the different control and experimental groups and their survival times.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Groups**                      **Characteristics**                                                                                                                                                           **Survival times**
  ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  1\. Controls **(C)**            Unoperated naive rats                                                                                                                                                         300 g body weight + 6 weeks **(C)** (*n* = 7)

  2\. 6-OHDA only **(L)**         Single injection of 24 μg 6-OHDA into the right medial forebrain bundle                                                                                                       Weeks after 6-OHDA **(L3W)** (*n* = 7)\
                                                                                                                                                                                                                6 weeks after 6-OHDA **(L6W)** (*n* = 7)\
                                                                                                                                                                                                                6 weeks + 1 month after 6-OHDA **(L6W1M)** (*n* = 7)\
                                                                                                                                                                                                                6 weeks + 3 months after 6-OHDA **(L6W3M)** (*n* = 6)\
                                                                                                                                                                                                                6 weeks + 6 months after 6-OHDA **(L6W6M)** (*n* = 6)\
                                                                                                                                                                                                                6 weeks + 9 months after 6-OHDA **(L6W9M)** (*n* = 6)

  3\. BoNT-A only **(B)**         Two injections of 1 ng BoNT-A \[solved in phosphate-buffered saline (PBS) supplemented with 0.1% bovine serum albumin (BSA)\], each at different sites within the right CPu   Weeks after BoNT-A **(B2W)** (*n* = 7)\
                                                                                                                                                                                                                1 month after BoNT-A **(B1M)** (*n* = 6)\
                                                                                                                                                                                                                months after BoNT-A **(B3M)** (*n* = 6)\
                                                                                                                                                                                                                6 months after BoNT-A **(B6M)** (*n* = 7)\
                                                                                                                                                                                                                9 months after BoNT-A **(B9M)** (*n* = 7)

  4\. 6-OHDA + BoNT-A **(LB)**    Single injection of 24 μg 6-OHDA into the right medial forebrain bundle followed by 2 × 1 ng BoNT-A                                                                           6 weeks after 6-OHDA + 1 month after BoNT-A **(LB6W1M)** (*n* = 9)\
                                                                                                                                                                                                                6 weeks after 6-OHDA + 3 months after BoNT-A **(LB6W3M)** (*n* = 8)\
                                                                                                                                                                                                                6 weeks after 6-OHDA + 6 months after BoNT-A **(LB6W6M)** (*n* = 8)\
                                                                                                                                                                                                                6 weeks after 6-OHDA + 9 months after BoNT-A **(LB6W9M)** (*n* = 8)

  5\. 6-OHDA + vehicle **(LV)**   Single injection of 24 μg 6-OHDA into the right medial forebrain bundle + 2 × 1 μl vehicle (PBS + 0.1% BSA)                                                                   6 weeks after 6-OHDA + 1 month after vehicle **(LV6W1M)** (*n* = 6)\
                                                                                                                                                                                                                6 weeks after 6-OHDA + 3 months after vehicle **(LV6W1M)** (*n* = 8)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Apomorphine rotation test
-------------------------

Successful 6-OHDA lesion as well as the effect of BoNT-A on motoric behavior were verified by the drug-induced apomorphine rotation test (Ungerstedt and Arbuthnott, [@B115]). All animals were examined in the apomorphine rotation test 1 month post 6-OHDA lesioning and repetitively over a time period of up to 9 months. Animals were placed in a self-constructed rotometer device modified according to Ungerstedt and Arbuthnott ([@B115]) 5 min after apomorphine injection (0.25 mg/kg, i. p.). Full rotations of 360° were counted over 40 min and the mean rotation per minute was calculated (anti-clockwise: +, clockwise: --).

Tissue processing
-----------------

For tissue processing brains were dissected, frozen in isopentane (−80°C) and cut in frontal sections (20 μm) on a cryostat (Leica Mikrosystems, Wetzlar, Germany). Mounting was performed on gelatin-coated and pre-cooled (−20°C) glass slides followed by a drying procedure (20--30 min, +35°C). Sections were obtained from 7 predefined levels, which were selected to cover the entire rostro-caudal extent of the CPu. The coordinates with reference to bregma were: level 1: +1.56 mm, level 2: −0.36 mm, level 3: −0.84 mm, level 4: −2.16 mm, level 5: −2.52 mm, level 6: −3.60 mm, and level 7: −5.20 mm (Paxinos and Watson, [@B92]). Each level consisted of immediately adjacent sections used for the visualization of the different receptor types, or of cell bodies.

Receptor autoradiography
------------------------

Autoradiography was performed according to published protocols (Zilles et al., [@B134],[@B136],[@B138], [@B135],[@B137]). The M~1~ receptor was labeled with \[^3^H\]pirenzepine (M~1~ antagonist), the agonistic binding site of the M~2~ receptor with \[^3^H\]oxotremorine-M, and its antagonistic binding site with \[^3^H\]AF-DX 384. The antagonistic ligand \[^3^H\]AF-DX 384 binds not only to M~2~ receptors, but also to M~4~ receptors in a regional specific manner (Valuskova et al., [@B117]). In the mouse striatum, almost 80% of this binding is to M~4~ receptors. The M~3~ receptor was labeled with \[^3^H\]4-DAMP (M~3~ antagonist) and the α~4~β~2~ nicotinic receptor with \[^3^H\]epibatidine (α~4~β~2~ agonist). All ligands were purchased from Perkin Elmer (Rodgau, Germany). Autoradiographic processing of the sections was performed in 3 main steps: rehydration and elimination of endogenous ligands, incubation with the respective tritiated ligand in the absence (total binding) or presence (nonspecific binding) of a specific non-radioactive ligand as displacer, and a final washing step to remove non-bound ligand and buffer salts. Sections were then dried and co-exposed with different plastic standards (representing different radioactivity concentrations) against ß-sensitive films (Kodak, PerkinElmer LAS GmbH, Germany) for 9 weeks (\[^3^H\]AF-DX 384, \[^3^H\]4-DAMP), 12 weeks (\[^3^H\]pirenzepine) or 15 weeks (\[^3^H\]epibatidine, \[^3^H\]oxotremorine-M). Resulting autoradiographs were developed using a Hyperprocessor (Amersham Biosciences, Amersham, UK; now: GE Healthcare Europe GmbH, Freiburg, Germany) and digitized with a CCD-camera (Zeiss, Carl Zeiss MikroImaging GmbH, Göttingen, Germany). Details of autoradiographic processing for each receptor are shown in Table [2](#T2){ref-type="table"}.

###### 

List of analyzed receptors with the respective specific ligands, nonradioactive displacers, washing, and incubation details.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Receptor**        **Ligand**                       **Displacer**           **Incubation buffer**                                                                                                                            **Pre-incubation**   **Main incubation**   **Final rinsing**
  ------------------- -------------------------------- ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- --------------------- ---------------------------------
  M~1~                \[^3^H\]-Pirenzepine 1.0 nM      Pirenzepine μm          Modified Krebs buffer (pH 7.4), 5.6 mM KCl, 30.6 mM NaCl, 1.2 mM MgSO~4~, 1.4 mM KH~2~PO~4~, 5.6 mM D-Glucose, 5.2 mM NaHCO~3~, 2.5 mM CaCl~2~   15 min, 4°C          60 min, 4°C           1\) × 1 min, 4°C\
                                                                                                                                                                                                                                                                           2) 1 s in distilled water, 22°C

  M~2~ (agonist)      \[^3^H\]-Oxotremorine-M 1.7 nM   Carbachol 10μm          20 mM HEPES-Tris (pH 7.5), 10 nM MgCl~2~, 300 nM Pirenzepine                                                                                     20 min, 22°C         60 min, 22°C          1\) × 2 min, 4°C\
                                                                                                                                                                                                                                                                           2) 1 s in distilled water, 22°C

  M~2~ (antagonist)   \[^3^H\]-AF-DX 384 5 nM          Atropinesulfate 100μm   Modified Krebs buffer (pH 7.4) 4.7 mM KCl 120 mM NaCl, 1.2 mM MgSO~4~, 1.2 mM KH~2~PO~4~, 5.6 mM D-Glucose, 25 mM NaHCO~3~, 2.5 mM CaCl~2~       15 min, 22°C         60 min, 22°C          1\) × 4 min, 4°C\
                                                                                                                                                                                                                                                                           2) 1 s in distilled water, 22°C

  M~3~                \[^3^H\]-DAMP 1 nM               Atropinesulfate 10μm    50 mM Tris-HCl (pH 7.4), 0.1 mM PMSF, 1 mM EDTA                                                                                                  15 min, 22°C         45 min, 22°C          1\) × 5 min, 4°C\
                                                                                                                                                                                                                                                                           2) 1 s in distilled water, 22°C

  α~4~β~2~            \[^3^H\]-Epibatidine 0.5 nM      Nicotine 100μM          15 mM Hepes (pH 7.5), 120 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl~2~, 1.8 mM CaCl~2~                                                                    20 min, 22°C         90 min, 22°C          1\) 1 × 5 min, 4°C\
                                                                                                                                                                                                                                                                           2) 1 s in distilled water, 22°C
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Histology
---------

Alternating sections were processed for the visualization of cell bodies. These sections were postfixed in 3.7% paraformaldehyde (20--45 min). Staining of cell bodies was performed with 0.1% cresyl-violet solution (7--12 min, 60°C; cresyl-violet acetate SIGMA C1791-5G). These sections were used as histological reference during the delineation of the CPu in the autoradiographs.

Image processing
----------------

The software MCID Analysis v7.0 (InterFocus imaging Ltd, Linton, UK) (<http://www.mcid.co.uk/>) was used for measurement of receptor densities. Digitized autoradiographs were loaded and regions of interest (ROIs) were defined manually by comparison with the neighbouting cell-body stained sections. For each ROI, the average and background-corrected gray values were extracted. For densitometric analysis the gray values of all processed sections were transformed into receptor densities (in fmol/mg protein) by means of standard curves derived from the co-exposed plastic standards. In the ensuing linearized autoradiographs, which can be color coded for visualization purposes, the receptor density in fmol/mg protein of each pixel can be calculated according to:
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where *R* is the radioactivity concentration in counts per minute \[cpm\], *C*~*b*~ is B~max~ and thus the binding site concentration in fmol/mg, *E* is the efficiency of the scintillation counter (depends on the actual counter), *B* is a constant representing the number of decays per unit of time and radioactivity \[Ci/min\], *W*~*b*~ the known equivalent protein weight of a standard \[mg\], *S*~*a*~ the specific activity of the ligand \[Ci/mmol\], *K*~*D*~ the dissociation constant of the ligand \[nM\], and *L* the free concentration of the ligand during incubation \[nM\]. Displayed receptor density values are the area-weighted means of all ROIs of an animal containing the CPu. Since the tritiated ligands do not only bind to a single receptor type, the *K*~*D*~ value for each ligand is important to reach the necessary selectivity for demonstration of a single receptor type. Therefore, the ligand concentration in the incubation buffer was set at 50% of the *K*~*D*~ value for the dissociation of the ligand-receptor binding. This results in a high specificity of receptor labeling.

Statistical analysis
--------------------

For all statistical observations, IBM SPSS Statistics version 20.0 was used. Gaussian distribution of receptor density values was tested with the Kolmogorov-Smirnov test. Then, data was analyzed with a between-subject Univariate General Linear Model (*post-hoc* ANOVA analysis of variance). The dependent variable was "receptor density" and the covariate was the respective treatment group separately for the left and right hemispheres not considering survival time followed by Bonferroni correction with the factor group \[*df* = 9; (M~1~ receptor: *F* = 1.199; M~2~ (agonist binding) receptor: *F* = 1.847, M~2~ (antagonist binding) receptor: *F* = 19.180, M~3~ receptor: *F* = 22.787, nAch receptor: *F* = 148.214)\]. Correlations between relative receptor density and apomorphine-induced rotations as well as time-dependent correlations of right-left differences were analyzed with linear regression followed by a two-sided Pearson correlation test. Possible significant differences in body weight between 2 groups were analyzed using factorial ANOVA. *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Quantitative *in vitro* receptor autoradiography was performed to analyze the mean densities of mAchRs (M~1~, M~2~, M~3~) and nAchRs (α~4~β~2~) longitudinally between 3 weeks and 9 months post lesion in 5 experimental groups (for details see Table [1](#T1){ref-type="table"}). Mean receptor densities and interhemispheric differences) of mAchRs and nAchRs are presented in Table [3](#T3){ref-type="table"}.

###### 

Summary of the mean receptor densities in the CPu for all analyzed receptors in fmol/mg protein ± SD and the interhemispheric difference (mean ± SD) (in %) for the 5 groups averaged over all post-lesion survival times \[controls (C), hemi-PD rats (L), BoNT-A only rats (B), hemi-PD + BoNT-A rats (LB) and hemi-PD + vehicle rats (LV)\].

  **Receptor**                                                 **Mean C**                            **Mean L**                                                                                                                                  **Mean B**                                                                                                   **Mean LB**                                                                                                                                     **Mean LV**
  ------------------------------------------------------------ ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  **M**~1~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Left hemisphere Right hemisphere Change (relative to left)   5,149 ± 2,335 5,263 ± 2,328 98 ± 1%   5,263 ± 1,190 4,772 ± 2,328 91 ± 5%                                                                                                         5,130 ± 1,414 5,083 ± 1,443 99 ± 6%                                                                          5,073 ± 1,328 4,905 ± 1,288 97 ± 6%                                                                                                             4,268 ± 1,591 3,958 ± 1,417 93 ± 5%
  **M**~2~ **(AGONIST BINDING)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Left hemisphere Right hemisphere Change (relative to left)   924 ± 82 974 ± 109 105 ± 7%           938 ± 70 887 ± 77 96 ± 7%                                                                                                                   965 ± 88 984 ± 82 98 ± 11%                                                                                   978 ± 85 936 ± 84 96 ± 8%                                                                                                                       862 ± 72 828 ± 81 96 ± 6%
  **M**~2~ **AND M**~4~ **(ANTAGONIST BINDING)**                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Left hemisphere Right hemisphere Change (relative to left)   3894 ± 363 3,859 ± 352 99 ± 2%        3,405 ± 190 2,877 ± 218[^\*\*\*^](#TN3){ref-type="table-fn"} 84 ± 5% [^\#\#\#^](#TN4){ref-type="table-fn"}                                  3,337 ± 197[^\*^](#TN1){ref-type="table-fn"} 3,085 ± 254[^\*\*\*^](#TN3){ref-type="table-fn"} 92 ± 9%        2,997 ± 216[^\*\*\*^](#TN3){ref-type="table-fn"} 2,595 ± 271[^\*\*^](#TN2){ref-type="table-fn"} 87 ± 9% [^\#\#\#^](#TN4){ref-type="table-fn"}   3,197 ± 180[^\*^](#TN1){ref-type="table-fn"} 2,737 ± 264[^\*\*\*^](#TN3){ref-type="table-fn"} 86 ± 6%
  **M**~3~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Left hemisphere Right hemisphere Change (relative to left)   7,274 ± 709 7,368 ± 757 101 ± 3%      4,999 ± 419[^\*\*\*^](#TN3){ref-type="table-fn"} 4,717 ± 417[^\*\*\*^](#TN3){ref-type="table-fn"} 94 ± 4%                                   5,398 ± 541[^\*\*\*^](#TN3){ref-type="table-fn"} 5,473 ± 486[^\*\*\*^](#TN3){ref-type="table-fn"} 101 ± 7%   4,853 ± 572[^\*\*\*^](#TN3){ref-type="table-fn"} 4,725 ± 613[^\*\*\*^](#TN3){ref-type="table-fn"} 97 ± 7%                                       5,316 ± 773[^\*\*\*^](#TN3){ref-type="table-fn"} 5,239 ± 745[^\*\*\*^](#TN3){ref-type="table-fn"} 99 ± 5%
  α~4~β~2~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Left hemisphere Right hemisphere Change (relative to left)   392 ± 35 382 ± 23 98 ± 7%             316 ± 25[^\*\*\*^](#TN3){ref-type="table-fn"} 136 ± 20[^\*\*\*^](#TN3){ref-type="table-fn"} 43 ± 5% [^\#\#\#^](#TN4){ref-type="table-fn"}   335 ± 23[^\*^](#TN1){ref-type="table-fn"} 354 ± 22 106 ± 7%                                                  331 ± 31[^\*^](#TN1){ref-type="table-fn"} 175 ± 23[^\*\*\*^](#TN3){ref-type="table-fn"} 53 ± 7%                                                 309 ± 20[^\*\*\*^](#TN3){ref-type="table-fn"} 135 ± 18[^\*\*\*^](#TN3){ref-type="table-fn"} 44 ± 8%

Asterisks indicate significance of a hemisphere to the respective side of the controls

*p \< 0.05*,

*p \< 0.01*,

p \< 0.001. Rhombs display interhemispheric significance within one group

*p \< 0.001. Significance was calculated with a between-subject Univariate General Linear Model (post-hoc ANOVA analysis of variance) using the mean receptor density of every treatment group separately for the left and right hemisphere*.

6-OHDA lesion effect on rotational behavior and body weight
-----------------------------------------------------------

The apomorphine-induced rotation test was performed 3 weeks post 6-OHDA lesion and 1 month post BoNT-A injection to functionally confirm dopaminergic deafferentiation after 6-OHDA lesion and the effect of BoNT-A on motoric behavior. All hemi-PD rats (groups L, LB, LV) demonstrated a contralateral net rotation of about 8 min^−1^ before the BoNT-A or vehicle injections. Intrastriatal BoNT-A injection in hemi-PD rats (group LB) significantly abolished contralateral rotations for up to 3 months. Vehicle injection in hemi-PD rats (group LV) did not affect the rotational behavior, as previously shown (Mann et al., [@B77]). TH-immunoreactive staining in the SNpc of both hemispheres revealed no side differences in control rats, a distinct loss of TH-positive neurons ipsilateral to the 6-OHDA lesion, and no additive effect of BoNT-A as previously shown (Mann et al., [@B77]). Body weight was not significantly different after BoNT-A administration (analyzed in groups LB and LV) 1 month and 3 months post intervention. Results expressed as weight ± SD were LB6W1M: 414 ± 44 g, LV6W1M: 457 ± 35 g, *p* = 0.069; LB6W3M: 476 ± 42 g, LV6W3M: 495 ± 52 g, *p* = 0.460.

Muscarinic M~1~ receptors
-------------------------

In the CPu of control rats (group C), M~1~ receptors showed a mean concentration of 5,092 ± 2,331 fmol/mg (mean ± SD) without significant interhemispheric differences (Figures [1A,C](#F1){ref-type="fig"}). 6-OHDA lesion (group L) non-significantly decreased interhemispheric M~1~ receptor density by about 9% ipsilateral to the lesion, the contralateral side remained at a level comparable to that of controls (Figures [1B,C](#F1){ref-type="fig"}). Notably, the potential effect of the 6-OHDA lesion on ipsilateral M~1~ receptors was more obvious in the first 3 months after 6-OHDA lesion (L3W −11.2%, L6W −10.2%, L6W1M −13.8%, L6W3M −9.5%, L6W6M −5.4%, L6W9M −4.1%) (*R*^2^ = 0.24083, *p* = 0.001) (Figure [1D](#F1){ref-type="fig"}).

![**(A,B)** Contrast-enhanced color-coded images showing the regional distribution of M~1~ receptor density labeled with \[^3^H\]pirenzepine in a control rat **(A,B)** after 6-OHDA lesion (group L6W1M) in a control rat **(A)** and after 6-OHDA lesion (group L6W1M) **(B)**. **(C)** Mean receptor density (fmol/mg protein; averaged over all post-lesion survival times) in the left/contralateral (black column) and right/ipsilateral hemispheres (gray column) of the 5 groups: C, control; L, 6-OHDA lesion; B, BoNT-A only; LB, L + BoNT-A; LV. L + vehicle. All data is expressed as means ± SD. **(D)** Scatter plots and regression analyses of the right-left differences of M~1~ receptor density for all 18 groups and time points (five groups with different survival times); see Table [1](#T1){ref-type="table"} for explanation of abbreviations. Significant regressions are labeled by a continuous line.](fnana-12-00065-g0001){#F1}

Injection of only BoNT-A (group B) did not result in interhemispheric differences when densities were averaged over all analyzed survival times (Figure [1C](#F1){ref-type="fig"}). Considering the post injection time course after application of BoNT-A in this group, there was an ipsilateral reduction of M~1~ receptor density of −7.0% 2 weeks after BoNT-A. This reduction significantly decreased (*R*^2^ = 0.71129, p = 0.001) with longer post injection survival (1 month −5.1%, 3 months −0.3%), and changed into an increase (6 months +2.4%, 9 months +5.1%) (Figure [1D](#F1){ref-type="fig"}).

BoNT-A injection in hemi-PD rats (group LB) did not significantly affect the right-left difference of M~1~ receptors when densities were averaged over all survival times (Figure [1C](#F1){ref-type="fig"}). Notably, the interhemispheric difference of group LB was reduced for all analyzed time points (LB6W1M −7.0%, LB6W3M −3.3%, LB6W6M −2.0% and LB6W9M −1.4%) (*R*^2^ = 0.15267, *p* = 0.022) (Figure [1D](#F1){ref-type="fig"}). Vehicle injection in hemi-PD rats (group LV) did not affect the 6-OHDA-induced imbalance of M~1~ receptor density (Figures [1C,D](#F1){ref-type="fig"}) as compared to group L.

To analyze a possible relation between interhemispheric differences and apomorphine-induced rotations and the effect of BoNT-A and Sham injection in this context, we correlated relative M~1~ receptor density with apomorphine-induced rotations for groups LB and LV and did not find a significant correlation (*R*^2^ = 0.009983, *p* = 0.7231).

Muscarinic M~2~ receptor (agonist binding)
------------------------------------------

M~2~ receptor density in the CPu of control rats (group C) exhibited a mean concentration of 949 ± 95 fmol/mg (mean ± SD) showing no significant side differences (Figures [2A,C](#F2){ref-type="fig"}). 6-OHDA lesioned animals (group L) demonstrated no significant interhemispheric differences (ipsilateral decrease of 6%) when the mean effect was calculated over the entire post injection time (Figures [2B,C](#F2){ref-type="fig"}). If this interhemispheric difference was analyzed along the post-injection time course, the right-left difference after 6-OHDA application was time-dependent (*R*^2^ = 0.12267, *p* = 0.025): −0.7% (L3W), 2.0% (L6W), −13.0% (L6W1M), −6.1% (L6W3M), −6.7% (L6W6M), −7.3% (L6W9M) (Figure [2D](#F2){ref-type="fig"}).

![**(A,B)** Contrast-enhanced color-coded images showing the regional distribution of M~2~ receptor density labeled with the agonist \[^3^H\]oxotremorine-M in a control rat **(A,B)** after 6-OHDA lesion (group L6W1M) in a control rat **(A)** and after 6-OHDA lesion (group L6W1M) **(B)**. **(C)** Mean receptor density (fmol/mg protein; averaged over all post-lesion survival times) in the left/contralateral (black column) and right/ipsilateral hemispheres (gray column) of the 5 groups (see Figure [1](#F1){ref-type="fig"}). All data is expressed as means ± SD. **(D)** Scatter plots and regression analyses of the right-left differences of M~2~ receptor density for all 18 groups and time points (five groups with different survival times); see Table [1](#T1){ref-type="table"} for explanation of abbreviations. Significant regressions are labeled by a continuous line.](fnana-12-00065-g0002){#F2}

Striatal M~2~ agonist binding of rats treated only with BoNT-A (group B) showed no significant interhemispheric differences when the mean was calculated over all post-injection time points (Figure [2C](#F2){ref-type="fig"}). However, values changed significantly (*R*^2^ = 0.59512, *p* = 0.001) depending on post-injection times of BoNT-A starting with an ipsilateral decrease at 2 weeks and ending with an increase at 9 months: −8% (B2W), −13.8% (B1M), −0.4% (B3M), 2.7% (B6M), 13.3% (B9M) (Figure [2D](#F2){ref-type="fig"}).

M~2~ agonist binding was not significantly altered by post-treatment of hemi-PD rats with BoNT-A (group LB) or with vehicle (group LV) when the mean effect was calculated over all survival times (Figure [2C](#F2){ref-type="fig"}). Rats of the LB group showed an interhemispheric compensation of the density reductions caused by 6-OHDA injections which reduced the difference in the ipsilateral side over time (*R*^2^ = 0.19002, *p* = 0.010): (LB6W1M −8.9%, LB6W3M −6.9%, LB6W6M 0.4%, LB6W9M 2.2%) (Figure [2D](#F2){ref-type="fig"}).

We found no significant correlation (*R*^2^ = 0.2559, *p* = 0.0544) between the interhemispheric difference of these M~2~ receptor binding sites for groups LB and LV and the apomorphine-induced rotations.

Muscarinic M~2~ and M~4~ receptor (antagonist binding)
------------------------------------------------------

In control rats (group C), a mean density of 3,876 ± 357 fmol/mg (mean ± SD) was measured. No significant interhemispheric differences were found (Figures [3A,C](#F3){ref-type="fig"}). Injection of 6-OHDA (group L) resulted in a significant ipsilateral decrease of antagonistic (\[^3^H\]-AFDX-384) binding of 16% when densities were averaged over all examined time points (Figures [3B--D](#F3){ref-type="fig"}). Furthermore, only densities of the ipsilateral hemisphere of group L animals were significantly lower than in controls. No significant correlation was found between receptor densities and post-injection time points (L6W1M −18.6%, L6W3M −15.4%, L6W6M −16.5%, L6W9M −15%) (Figure [3D](#F3){ref-type="fig"}).

![**(A,B)** Contrast-enhanced color-coded images showing the regional distribution of M~2~ and M~4~ receptor densities receptor density labeled with the antagonist \[^3^H\]AF-DX 384 in a control rat **(A,B)** after 6-OHDA lesion (group L6W6M) in a control rat **(A)** and after 6-OHDA lesion (group L6W6M) **(B)**. **(C)** Mean receptor density (fmol/mg protein; averaged over all post-lesion survival times) in the left/contralateral (black column) and right/ipsilateral hemispheres (gray column) of the five groups (see Figure [1](#F1){ref-type="fig"}). All data is expressed as means ± SD. Asterisks mark significant differences to the respective side of controls (^\*^*p* \< 0.05, ^\*\*\*^*p* \< 0.001). Rhombs signs highlight interhemispheric significance within each group (^\#\#\#^*p* \< 0.001). **(D)** Scatter plots and regression analyses of the right-left differences of M~2~ receptor density for all 18 groups and time points (five groups with different survival times); see Table [1](#T1){ref-type="table"} for explanation of abbreviations. Significant regressions are labeled by a continuous line.](fnana-12-00065-g0003){#F3}

Treatment with BoNT-A only (group B) resulted in a non-significant interhemispheric decrease (−8%) in antagonistic receptor binding when densities were averaged over all examined time points (Figure [3C](#F3){ref-type="fig"}). However, the densities were significantly lower in both hemispheres of group B rats compared to those of control animals (Figure [3C](#F3){ref-type="fig"}). Values changed significantly (*R*^2^ = 0.68926, *p* = 0.0001) depending on post BoNT-A injection-time, starting with an ipsilateral decrease at 2 weeks and ending with a slight increase at 9 months: −16% (B2W), −10.9% (B1M), −9.4% (B3M), −0.6% (B6M), 3.5% (B9M) (Figure [3D](#F3){ref-type="fig"}).

Group LB, but not group LV, showed a significant interhemispheric difference in receptor density if antagonistic binding sites were averaged over all examined time points (Figure [3C](#F3){ref-type="fig"}). Both groups presented significantly lower densities of antagonistic binding sites in both hemispheres if compared to controls (Figure [3C](#F3){ref-type="fig"}). A significant time-dependent BoNT-A-induced effect on the 6-OHDA induced binding site density (group LB) is disclosed in the longer post injection periods (*R*^2^ = 0.317, *p* = 0.0001): (LB6W1M −19.8%, LB6W3M −16.5%, LB6W6M −10.1%, LB6W9M −7.7% (Figure [3D](#F3){ref-type="fig"}). Contrastingly, the vehicle injection in hemi-PD rats (group LV) did not influence the 6-OHDA induced M~2~ receptor density (Figures [3C,D](#F3){ref-type="fig"}).

Right-left differences for groups LB and LV did not correlate (*R*^2^ = 0.1247, *p* = 0.1966) with motor behavior in the apomorphine rotation test.

Muscarinic M~3~ receptor
------------------------

A mean (± SD) density of 7,321 ± 733 fmol/mg was found for M~3~ receptors in control rats (group C) (Figures [4A,C](#F4){ref-type="fig"}). The differences between both hemispheres are not significant in any of the examined control and experimental groups when values are averaged over all post-injection time points (Figures [4B,C](#F4){ref-type="fig"}). However, the M~3~ receptor density is significantly lower in both hemispheres of the experimental groups (L, B, LB, LV) compared to the drug naïve rats (group C) (Figure [4C](#F4){ref-type="fig"}).

![**(A,B)** Contrast-enhanced color-coded images showing the regional distribution of M~3~ receptor density labeled with \[^3^H\]4-DAMP in a control rat **(A,B)** after 6-OHDA lesion (group L6W1M) in a control rat **(A)** and after 6-OHDA lesion (group L6W1M) **(B)**. **(C)** Mean receptor density (fmol/mg protein; averaged over all post-lesion survival times) in the left/contralateral (black column) and right/ipsilateral hemispheres (gray column) of the five groups (see Figure [1](#F1){ref-type="fig"}). All data is expressed as means ± SD. Asterisks mark significant differences to the respective side of controls (^\*\*\*^*p* \< 0.001). **(D)** Scatter plots and regression analyses of the right-left differences of M~2~ receptor density for all 18 groups and time points (five groups with different survival times); see Table [1](#T1){ref-type="table"} for explanation of abbreviations. Significant regressions are labeled by a continuous line.](fnana-12-00065-g0004){#F4}

A significant (*R*^2^ = 0.309, *p* = 0.001) time dependence of the BoNT-A effect (group B) on the M~3~ receptor densities was observed: −3% (B2W), --.3% (B1M), −2.0% (B3M), 4.4% (B6M), 7.8% (9M) (Figure [4D](#F4){ref-type="fig"}). The hemi-PD rats with injection of BoNT-A (group LB) also presented a significant (*R*^2^ = 0.16436, *p* = 0.020) post-injection time dependency (LB6W1M −5.6%, LB6W3M −5.1%, LB6W6M +0.6%, LB6W9M −1.4%) (Figure [4D](#F4){ref-type="fig"}). In the vehicle-injected group (LV), the M~3~ receptor density was comparable to that of hemi-PD rats (group L) (Figures [4C,D](#F4){ref-type="fig"}).

We observed no significant (*R*^2^ = 0.1433, *p* = 0.1643) correlation between the right-left difference of M~3~ receptor density in the CPu of groups LB and LV and the apomorphine-induced rotational behavior.

Nicotinic α~4~β~2~ receptor
---------------------------

Nicotinic α~4~β~2~ receptors exhibited a density of 387 ± 29 fmol/mg (mean ± SD) in the CPu of control rats (group C), and no significant interhemispheric differences were observed (Figures [5A,C](#F5){ref-type="fig"}). A significant reduction of 57% ipsilateral to the 6-OHDA application (group L) was found. The decrease remained constant up to 9 months after 6-OHDA injection (Figures [5B--D](#F5){ref-type="fig"}). Furthermore, this obvious interhemispheric difference was also seen in the hemi-PD rats treated with BoNT-A (group LB) or vehicle (group LV). A significant, but low reduction in binding site densities is also found on the contralateral side of all experimental groups (L, B, LB, LV) if compared to drug naïve controls (Figure [5C](#F5){ref-type="fig"}).

![**(A,B)** Contrast-enhanced color-coded images showing the regional distribution of nicotinic α~4~β~2~ receptor density labeled with \[^3^H\]epibatidine in a control rat **(A,B)** after 6-OHDA lesion (group L6W3M) in a control rat **(A)** and after 6-OHDA lesion (group L6W3M) **(B)**. **(C)** Mean receptor density (fmol/mg protein; averaged over all post-lesion survival times) in the left/contralateral (black column) and right/ipsilateral hemispheres (gray column) of the five groups (see Figure [1](#F1){ref-type="fig"}). All data is expressed as means ± SD. Asterisks mark significant differences to the respective side of controls (^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001). Rhombs signs highlight interhemispheric significance within each group (^\#\#\#^*p* \< 0.001). **(D)** Scatter plots and regression analyses of the right-left differences of M~2~ receptor density for all 18 groups and time points (five groups with different survival times); see Table [1](#T1){ref-type="table"} for explanation of abbreviations. Significant regressions are labeled by a continuous line. **(E)** Relationship between interhemispheric differences in the α~4~β~2~ receptor densities of groups (LB and LV) and rotational behavior (anti-clockwise: +, clockwise: --).](fnana-12-00065-g0005){#F5}

Treatment with BoNT-A only (group B) did not result in significant interhemispheric differences when densities were averaged over all post-injection time points (Figure [5C](#F5){ref-type="fig"}), although the receptor density of the ipsilateral hemisphere decreased significantly (*R*^2^ = 0.2678, *p* = 0.002) from values well above control levels at 2 weeks to 3 months after BoNT-A to control values at 6 and 9 months post-injection (B2W 9.0%, B1M 7.6%, B3M 11.4%, B6M 0.1%, B9M 0.7%) (Figure [5D](#F5){ref-type="fig"}).

If the time-dependency after BoNT-A injection was analyzed (group LB, Figure [5D](#F5){ref-type="fig"}), a significant (R^2^ = 0.174, p = 0.014) negative correlation between interhemispheric differences and increasing post-injection times was found (LB6W1M −41.8%, LB6W3M −53.4%, LB6W6M −46.2%, LB6W9M −51.8%) (Figure [5D](#F5){ref-type="fig"}). In vehicle-injected hemi-PD rats (LV) nicotinic receptors equaled those of group L (Figures [5C,D](#F5){ref-type="fig"}).

A highly significant correlation (*R*^2^ = 0.5493, *p* = 0.0016) of the interhemispheric difference of nicotinic receptors in the groups LB and LV and apomorphine-induced rotations was found (Figure [5E](#F5){ref-type="fig"}).

Summary of important results
----------------------------

Unilateral injection of 6-OHDA into the MFB (group L) leads to a 10% decrease of M~1~ receptor densities 3 weeks after 6-OHDA application, and a restitution to control values 9 months later (Figure [1D](#F1){ref-type="fig"}). The M~2~/M~4~ receptors (agonistic binding site) show control values 3 weeks after 6-OHDA application followed by a decrease of \~10% over the subsequent 9 months (Figure [2D](#F2){ref-type="fig"}). The M~2~ receptor (antagonistic binding site) and the M~3~ receptor are also decreased by \~10% compared to control value, but do not show any significant recovery over time (Figures [3D](#F3){ref-type="fig"}, [4D](#F4){ref-type="fig"}). The nicotinic α~4~β~2~ receptor shows the most obvious decrease in density (50--60%) 3 weeks after 6-OHDA injection, but no sign of any recovery during the following period (Figure [5D](#F5){ref-type="fig"}).

Injection of BoNT-A into the striatum of drug naïve rats (group B) leads to an initial (2 weeks after injection) decrease in M~1~ and M~3~ receptor densities of about 5--10% followed by a steady recovery, reaching 5--10% over the control value 9 months later (Figures [1D](#F1){ref-type="fig"}, [4D](#F4){ref-type="fig"}). Also the M~2~ receptor (agonistic binding site) show an initial decrease of slightly more than 10%, followed by a steep increase resulting in a density of \~10% over control values 9 months after BoNT-A treatment (Figure [2D](#F2){ref-type="fig"}). The antagonistic binding sites of the M~2~/M~4~ receptor start with a density nearly 20% below control level, and come back to control levels 9 months later (Figure [3D](#F3){ref-type="fig"}). The nicotinic α~4~β~2~ receptor shows a completely different reaction. It starts with a 10% higher density than control values 2 weeks after BoNT-A injection, and returns to control values during the following period (Figure [5D](#F5){ref-type="fig"}).

Injection of BoNT-A into the 6-OHDA lesioned striatum (group LB) leads to an M~1~ receptor density which is well comparable to that of the untreated (group L) and vehicle injected (group LV) hemi-PD rats over all time points (Figure [1D](#F1){ref-type="fig"}). The decrease in M~2~ (agonist and antagonist binding sites) and M~3~ receptor densities caused by 6-OHDA application is compensated by BoNT-A, since changes over time in the densities of these receptors in the LB group result in values comparable to those of controls 9 months after BoNT-A injection (Figures [2D](#F2){ref-type="fig"}, [4D](#F4){ref-type="fig"}). The nicotinic α~4~β~2~ receptor shows an initial 15% increase of its density when groups L and LB are compared. However, the receptor density decreases during the following period and in the hemiPD rats treated with BoNT-A (LB group) reaches nearly the values of the untreated hemi-PD (L group) rats (Figure [5D](#F5){ref-type="fig"}). The large difference between the non-lesioned but BoNT-A treated rats (group B) and the BoNT-A treated hemi-PD rats (group LB) is remarkable and may indicate a strong effect of 6-OHDA lesions on the expression of the nicotinic α~4~β~2~ receptor. This is also supported by the conspicuously large decrease of the α~4~β~2~ receptors after 6-OHDA lesioning.

Most notable is the fact that BoNT-A injection causes a negative correlation between nicotinic α~4~β~2~ receptor densities and post-injection time in drug naïve (group B) and BoNT-A treated (group LB) hemi-PD rats, but results in a positive correlation between all examined muscarinic cholinergic binding site (M~1~, M~2~/M~4~ (agonist and antagonist) and M~3~) densities. Apparently, the nicotinic and muscarinic receptors react differentially to BoNT-A treatment.

Discussion {#s4}
==========

Progressive dopaminergic cell death and the consequent DA deficit in the CPu can only partly explain PD\'s symptomatology, hence various compensatory changes in dopaminergic and other neurotransmitter systems have been described (Barone, [@B10]). Here, we applied quantitative *in vitro* receptor autoradiography to analyze time-dependent changes in the densities of mAchRs (M~1~, M~2~, M~3~, M~4~) and nAchRs (α~4~β~2~) in hemi-PD rats with or without unilateral BoNT-A injection into the striatum. Receptor densities were measured in the striatum ipsi- and contralateral to the 6-OHDA injection side, and expressed as relative values by calculating the difference between ipsilateral and contralateral receptor densities normalized by the contralateral density. BoNT-A was injected ipsilaterally.

Five experimental groups were analyzed up to a survival time of 9 months to uncover changes in hemi-PD rat striata and to disclose possible receptor-related explanations for the positive motor effect of BoNT-A in hemi-PD rats (Wree et al., [@B125]; Antipova et al., [@B3]; Mann et al., [@B76],[@B77]). To confirm successful 6-OHDA lesion we performed apomorphine-induced rotational testing. As dopaminergic deprivation with 6-OHDA increased ipsilateral striatal D~2~/D~3~ receptor density (Creese et al., [@B28]; Creese and Snyder, [@B29]; Murrin et al., [@B87]; Staunton et al., [@B108]; Przedbroski et al., [@B96]; Sun et al., [@B110]; Choi et al., [@B24]), the ipsilateral CPu of hemi-PD rats is inhibited more than the left by application of the D~2~/D~3~ agonist apomorphine. Hemi-PD rats start to rotate contralateral to the 6-OHDA lesion. Animals which demonstrated at least 4 rotations per minute were seen as successfully lesioned confirming dopaminergic depletion of about 97% (Ungerstedt and Arbuthnott, [@B115]).

Striatal organization and cholinergic neurotransmission
-------------------------------------------------------

The majority of striatal neurons (about 95%; Oorschot, [@B90]) are medium spiny cells (MSN), a GABAergic projection neuron. About 50% express substance P, dynorphin and dopamine D~1~ receptors, and project to the globus pallidus internus and substantia nigra pars reticulata (SNpr) (direct basal ganglia loop), whereas the other half of the MSNs express enkephalin as well as dopamine D~2~ receptors and mainly project to the globus pallidus externus (EGP) (indirect basal ganglia loop; Bolam et al., [@B18]). The remaining 3--5% are interneurons and can be subdivided into at least 4 subtypes. Three of them are GABAergic interneurons expressing either parvalbumin, somatostatin or calretinin. The fourth subtype is a large tonically active aspiny cholinergic interneuron (Kawaguchi, [@B63]; Kawaguchi et al., [@B64]). Cholinergic neurotransmission in the CPu arises predominantly from these cholinergic interneurons, but also from an external cholinergic projection from the pedunculopontine and laterodorsal tegmental area (Woolf and Butcher, [@B124]; Dautan et al., [@B32]). Moreover, a weak cholinergic input was described to come from the nucleus basalis Meynert (Mesulam, [@B83]).

Localization of cholinergic receptors
-------------------------------------

In the CPu, M~1~ receptors are expressed on MSNs (Araujo et al., [@B6]; Hersch et al., [@B50]; Yung et al., [@B129]; Muccioli et al., [@B85]; Alcantara et al., [@B1]; Yan et al., [@B128]; Bauer et al., [@B11]; Haghir et al., [@B45]). M~2~ receptors are also located on MSNs and ChAT-ir interneurons (Mash and Potter, [@B79]; Hersch et al., [@B50]; Bernard et al., [@B14]; Bauer et al., [@B11]; Haghir et al., [@B45]). M~3~ receptors are found on MSNs and on terminals of cortical and thalamic afferents (Zubieta and Frey, [@B140]; Levey et al., [@B71]; Yan et al., [@B128]; Haghir et al., [@B45]). M~4~ receptors are found in spines of MSNs of striatal neurons (Levey et al., [@B72]; Hersch et al., [@B50]). Within the CPu, nAchR are described predominantly on nigrostriatal and also corticostriatal terminals, and ChAT-ir interneurons (Hunt and Schmidt, [@B55]; Schwartz and Kellar, [@B103]; Clarke et al., [@B25]; Happe et al., [@B46]; Arroyo-Jim nez et al., [@B7]; Kaiser and Wonnacott, [@B61]; Jones et al., [@B59]; Pradhan et al., [@B95]).

Cholinergic and dopaminergic interaction
----------------------------------------

The dopaminergic and cholinergic systems can regulate one another\'s function in a bidirectional manner (Havekes et al., [@B47]). Receptors play a key role in this issue. Activation of dopamine D~2~ receptors inhibits Ach release (Maurice et al., [@B80]), whereas the D~1~ receptors facilitate it (Joyce, [@B60]). The nAchRs and mAchRs (M~1~−M~5~) were both described to mediate DA release from dopaminergic terminals. However, studies report conflicting results on the DA inhibiting or facilitating effects. The role of different receptor subtypes, especially of mAchRs located on MSNs and corticostriatal or thalamostriatal afferents (Woolf and Butcher, [@B123]; Schoffelmeer et al., [@B101]; Xu et al., [@B126]; De Klippel et al., [@B35]; Calabresi et al., [@B21]; Zhang et al., [@B131]; Bendor et al., [@B13]; Havekes et al., [@B47]) is not completely understood. NAchRs located on dopaminergic axons were described to regulate DA release (Sharples et al., [@B105]; Wonnacott et al., [@B122]; Zhou et al., [@B132]). Moreover, due to the regulation of Ach release of the cholinergic interneurons via autoreceptors (M~2~ + M~4~), the DA release of dopaminergic terminals is modified indirectly by mAchRs via nAchRs (Raiteri et al., [@B97]). A recent publication postulated a change in the impact of Ach on the regulation of DA release (reducing or increasing) at DA terminals depending on the firing mode of the respective DA neuron (Threlfell et al., [@B112]). DA neurons exhibit two different states of firing modes in rats *in vivo*: a single-spike mode at a frequency of about 1--10 Hz, and a burst firing mode of 3--5 spikes at a frequency of about 15--100 Hz which is interrupted by short-term pauses (Hyland et al., [@B56]). Ach acting on β~2~ subunits of nAchRs on nigrostriatal terminals provokes DA release in terminals during the single-spike mode, but inhibits DA release at terminals in the burst firing mode (Zhou et al., [@B132]; Rice and Cragg, [@B100]; Zhang and Sulzer, [@B130]). Activation of mAchRs (M~2~, M~4~) results in decreased Ach release from cholinergic interneurons, and by this in a reduced activation of nAchR on dopaminergic axons. Consequently, inhibition of DA release is observed after activation of mAchRs for single-spike modes of DA neurons, activation is found for burst firing mode (Threlfell et al., [@B112]).

Muscarinic receptors in PD and hemi-PD
--------------------------------------

Studies on mAchR binding in the CPu of PD patients using post-mortem brain tissue (Aubert et al., [@B9]; Lange et al., [@B67]; McOmish et al., [@B81]) are partly contradictory and have been summarized together with animal experiments in Table [4](#T4){ref-type="table"}. Lange et al. ([@B67]) postulated a decrease in M~1~ receptor density of the striatum and an unaltered M~2~ receptor density in PD brain tissue compared to controls (Lange et al., [@B67]). McOmish et al. ([@B81]) recently found no changes in M~1~ and M~2~ receptor densities, but an increased M~3~ receptor density in the CPu of PD patients (McOmish et al., [@B81]).

###### 

Striatal changes in cholinergic receptor densities in human PD patients and different animal models of PD.

  **Receptor subtype**   **Species/Animal model**   **Survival time**   **Detection method**                 **Ligand**                             **Effects**          **References**
  ---------------------- -------------------------- ------------------- ------------------------------------ -------------------------------------- -------------------- ------------------------
  M~1~                   Human PD patient           --                  Binding in post-mortem homogenates   \[^3^H\]pirenzepine                    Decrease             Lange et al., [@B67]
  M~1~                   Human PD patient           --                  Binding in post-mortem slices        \[^3^H\]pirenzepine                    Unaltered            McOmish et al., [@B81]
  M~1~                   MFB-lesioned 6-OHDA rat    1 year              Autoradiography                      \[^3^H\]pirenzepine                    Decrease (26%)       Dawson et al., [@B33]
  M~1~                   SN-lesioned 6-OHDA rat     3 weeks             Autoradiography                      \[^3^H\]pirenzepine                    Decrease (25--29%)   Joyce, [@B60]
  M~1~                   MFB-lesioned 6-OHDA rat    3 weeks             Autoradiography                      \[^3^H\]pirenzepine                    Unaltered            Wang et al., [@B119]
  M~1~                   MFB-lesioned 6-OHDA rat    10-13 days          SPECT                                \[^123^I\]iododexetimide               Unaltered            Knol et al., [@B65]
  M~2~                   Human PD patients          --                  Binding in post-mortem homogenates   \[^3^H\]oxotremorine-M                 Unaltered            Lange et al., [@B67]
  M~2~                   Human PD patients          --                  Binding in post-mortem slices        \[^3^H\]AF-DX 384                      Unaltered            McOmish et al., [@B81]
  M~2~                   SN-lesioned 6-OHDA rat     3 weeks             Autoradiography                      \[^3^H\]NMS (+unlabeled pirenzipine)   Decrease (27%)       Joyce, [@B60]
  M~2~                   Pitx3ak mice               4--6 months         Autoradiography                      \[^3^H\]oxotremorine-M                 Decrease (19%)       Cremer et al., [@B30]
  M~3~                   Human PD patients          --                  Binding in post-mortem slices        \[^3^H\]4DAMP                          Increase             McOmish et al., [@B81]
  M~3~                   Pitx3ak mice               4--6 months         Autoradiography                      \[^3^H\]4DAMP                          Unaltered            Cremer et al., [@B30]
  M~1~-M~5~              MFB-lesioned 6-OHDA rat    8 weeks             Autoradiography                      \[^3^H\]QNB                            Decrease (12--17%)   Araki et al., [@B5]
  nAch                   Human PD patients          --                  Binding in post-mortem homogenates   \[^3^H\]nicotine                       Unaltered            Lange et al., [@B67]
  nAch                   Human PD patients          --                  Binding in post-mortem slices        \[^3^H\]methylcarbamylcholine          Decrease (74%)       Aubert et al., [@B9]
  nAch                   Human PD patients          --                  PET                                  2-\[^18^F\]FA-85380                    Decrease (20%)       Meyer et al., [@B84]
  nAch                   MFB-lesioned 6-OHDA rat    2 weeks             Ligand-binding techniques            \[^3^H\]epibatidine                    Decrease (50%)       Zoli et al., [@B139]
  nAch                   MPTP-treated monkeys       4 weeks             Autoradiography                      \[^123^I\]epibatidine                  Decrease (40-50%)    Kulak et al., [@B66]
  nAch                   MFB-lesioned 6-OHDA rat    3 weeks             Autoradiography                      \[^125^I\]epibatidine                  Decrease (36%)       Pradhan et al., [@B95]
  nAch                   MFB-lesioned 6-OHDA rat    4--5 weeks          Autoradiography                      \[^125^I\]epibatidine                  Decrease (47%)       Perez et al., [@B93]
  nAch                   Pitx3ak mice               4--6 months         Autoradiography                      \[^3^H\]epibatidine                    Decrease (47%)       Cremer et al., [@B30]

*The table summarizes the main studies of this field*.

M~2~ receptors contain a high and a low affinity binding site (Birdsall et al., [@B16]; Giraldo et al., [@B42]). Here, we investigated the high affinity binding site of the M~2~ receptor with the agonist \[^3^H\]oxotremorine-M and the high and low affinity binding site with the antagonist \[^3^H\]AF-DX 384. Furthermore, it must be noted that \[^3^H\]AF-DX 384 also binds to the antagonistic site of the M~4~ receptor, and about 80% of the sites labeled with this ligand in the mouse striatum correspond to the M~4~ and not the M~2~ receptor (Levey et al., [@B72]; Hersch et al., [@B50]; Valuskova et al., [@B117]). Consequently, we found an about four times higher mean density with \[^3^H\]AF-DX 384 than with the more M~2~ subtype-specific \[^3^H\]oxotremorine-M throughout all experimental groups (Figures [2C](#F2){ref-type="fig"}, [3C](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}). This is in line with the measurement of Svensson et al. ([@B111]) who described that the high affinity binding sites constitute about 27% and the low affinity site about 73% (Svensson et al., [@B111]). Interestingly, only the \[^3^H\]AF-DX 384 binding significantly decreases after 6-OHDA lesioning (Figure [3C](#F3){ref-type="fig"}), and slowly returns to control values after BoNT-A injection (Figure [3D](#F3){ref-type="fig"}). With the presently available tritiated ligands it cannot be clarified whether this decrease is caused by the higher binding of M~4~ than M~2~ receptors.

In hemi-PD rats, all mAchR densities were decreased ipsilateral to the lesion between 6% and 16% as compared to the contralateral hemisphere. Our findings on 6-OHDA-induced changes of mAchRs are partly in line with others: Araki et al. ([@B5]) showed that dopaminergic depletion by 6-OHDA injection into the MFB decreased binding of \[^3^H\]QNB (labeling subtypes M~1~-M~5~; Jakubík et al., [@B58]) by 12--17% 8 weeks post lesion (Araki et al., [@B5]). Similar experiments resulted in a striatal decrease of M~1~ receptor density of 26% using the selective antagonist \[^3^H\]pirenzepine about 1 year after deafferentiation (Dawson et al., [@B33]), and also a decrease in \[^3^H\]pirenzepine binding of 25% to 29% after intranigral 6-OHDA application (Joyce, [@B60]). However, contradictory results were published by Wang et al. ([@B119]) who found no changes in \[^3^H\]pirenzepine binding 3 weeks post 6-OHDA lesion of the MFB (Wang et al., [@B119]) as well as by Knol et al. ([@B65]) describing unaltered striatal M~1~ receptor density with the \[^123^I\]iododexetimide SPECT method. Besides the small general reduction of the striatal M~1~ receptor density ipsilateral to the 6-OHDA lesion, we found a positive correlation between the right-left difference and the survival time between 3 weeks and 9 months. M~2~ receptors measured using \[^3^H\]NMS in the presence of unlabeled pirenzepine decreased by about 27% in the lateral CPu after intranigral 6-OHDA injection (Joyce, [@B60]). Also in Pitx3ak mice, which exhibit a severe loss of dopaminergic cells in the SNpc, M~2~ receptor density (agonist binding) in the CPu was significantly reduced by 19% (Cremer et al., [@B30]). In addition to the initial marked reduction of M~2~ receptor density induced by dopaminergic deafferentiation, the M~2~ receptor densities further significantly decreased with longer post lesion survival times up to 9 months in the present study. We found significant reductions of M~3~ receptor densities, notably in both hemispheres, after 6-OHDA lesion. This is in contrast to results in the CPu of DA depleted Pitx3ak mice, where Cremer et al. ([@B30]) found no significant change in M~3~ receptor densities as compared to wildtype mice. This contradiction may be explainable by the completely different PD models in the work of Cremer et al. ([@B30]) and the present study.

When inducing hemi-PD by 6-OHDA injection, we did not use desipramine application ahead (Mailman, [@B75]; López-Giménez et al., [@B74]; Nash and Brotchie, [@B88]) in order to avoid binding of this substance to various receptors, and thus to ensure comparability between all experimental groups including BoNT-A treatment (Wree et al., [@B125]; Antipova et al., [@B3]; Hawlitschka et al., [@B48]; Mehlan et al., [@B82]). Notably, lesion of the locus coeruleus did not cause changes in mAchR densities using \[^3^H\]QNB binding (Sharma et al., [@B104]). Moreover, striatal Ach levels and M~1~ receptor density did not show any changes after specific noradrenergic depletion with the selective noradrenergic neurotoxin N-2-chloroethyl-N-ethyl-2-bromobenzylamine (DSP-4) (Asanuma et al., [@B8]). Following dopaminergic depletion the densities of all mAchRs were found to be reduced in the present study. As there is no evidence in recent literature for the localization of mAchRs on dopaminergic axon terminals (Jones et al., [@B59]; Zhou et al., [@B132]), the reduction of mAchR densities can probably not be explained by 6-OHDA-induced axonal degeneration. Rather, the hyperactivity of striatal cholinergic neurotransmission due to dopaminergic denervation of the CPu and the subsequently increased Ach levels in hemi-PD rats (DeBoer et al., [@B34]; Muma et al., [@B86]; Rakovska et al., [@B98]) might result in a downregulation of mAchRs. This assumption is in line with findings that chronic inhibition of acetylcholinesterase inducing increased Ach concentrations also leads to a significant decrease of about 20% in mAchR densities as revealed by \[^3^H\]QNB binding (Sivam et al., [@B106]; Yamada et al., [@B127]).

Muscarinic receptors in BoNT-A-injected rats
--------------------------------------------

BoNT-A injection in control animals always led to an interhemispheric right-left difference of mAchRs between −7 and −16% 2 weeks after injection that significantly diminishes over time and even resulted in an ipsilateral increase in receptor densities between 3.5 and 13.3% 9 months later. BoNT-A injection in hemi-PD rats significantly affected overall interhemispheric differences for M~2~/M~4~ (antagonist binding) and M~3~ receptors, whereas differences of M~1~, and M~2~ (agonist binding) receptors were not significantly changed (Figures [1C](#F1){ref-type="fig"}, [4C](#F4){ref-type="fig"}). However, considering the time course of the BoNT-A effect in hemi-PD rats, interhemispheric differences in mAchR densities diminished with increasing survival time. The effect of BoNT-A on mAchR densities found in hemi-PD rats, however, did not correlate with changes in apomorphine-induced rotations. Seemingly, the positive effect of BoNT-A on motor behavior in hemi-PD rats for up to 6 months (Wree et al., [@B125]) cannot be based on changes in mAchR densities.

Nicotinic receptors in PD and hemi-PD
-------------------------------------

In PD patients striatal nAchRs levels were analyzed with conflicting results (see Table [4](#T4){ref-type="table"} for a summary): Aubert et al. ([@B9]) using *in vitro* receptor autoradiography reported a decrease by 74%, and Meyer et al. ([@B84]) using PET analysis with 2-\[^18^F\]FA-85380 found a reduction of 20%. However, Lange et al. ([@B67]) evaluating *in vitro* receptor binding studies did not find changes in the caudate nucleus or in the putamen. In the CPu of MPTP-treated squirrel monkeys nAchRs density was also reported to decline by 40% to 50% using \[^3^H\]epibatidine (Kulak et al., [@B66]).

Hemi-PD rats showed a massive ipsilateral decrease in striatal nAchRs of more than 50%. This effect was constant up to a survival time of 9 months. This confirms previous studies: Zoli et al. ([@B139]) demonstrated an ipsilateral decrease of 50% in nAchR density using \[^3^H\]epibatidine 2 weeks after 6-OHDA, Pradhan et al. ([@B95]) reported a decrease of about 36% of \[^125^I\]epibatidine binding 3 weeks post 6-OHDA, and Perez et al. ([@B93]) an ipsilateral decrease of 47%. Vehicle injections did not cause any nAchR changes in the CPu (Pradhan et al., [@B95]). The lesion studies in rats are in line with findings in the dopamine-depleted Pitx3ak mouse, where striatal nAchR density was also drastically reduced by 47% relative to control animals (Cremer et al., [@B30]).

This dramatic loss of nAchR density after destruction of dopaminergic SNpc neurons may be explained by the predominant localization of nAchRs on dopaminergic axonal terminals (Kaiser and Wonnacott, [@B61]; Jones et al., [@B59]; Pradhan et al., [@B95]). About 50% of the striatal nAchRs are located on cortical afferents or striatal interneurons (Zoli et al., [@B139]), thus explaining the remaining striatal \[^3^H\]epibatidine binding after 6-OHDA lesion.

Nicotinic receptors in BoNT-A-injected rats
-------------------------------------------

NAchRs were slightly increased ipsilateral one month after BoNT-A injection. However, a time dependence was detected: this initial increase was followed thereafter by a normalization to control values. In BoNT-A injected hemi-PD rats the interhemispheric difference of nAchRs density significantly diminished by about 10% compared to both the vehicle-injected rats (group LV) and the drug naïve hemi-PD rats (group L). Thus, BoNT-A induced an increase of nAchR density in groups B and LB.

Seemingly, BoNT-A induced an increase of nAchRs on non-dopaminergic structures, e.g., cortical afferents or striatal interneurons, since dopaminergic terminals no longer exist in hemi-PD. An initially increased nAchR density compared to controls and vehicle-injected rats was found after BoNT-A injection which may be explained by the reduction of striatal Ach content and a concomitant upregulation of nAchRs. This effect, however, disappears after 6--9 months after BoNT-A injection. Interestingly, the opposite effect of BoNT-A was seen in mAchR densities; here the reduction in striatal Ach content was followed by a downregulation of mAchR densities.

This study expands our understanding of 6-OHDA- and BoNT-A-induced changes in striatal mAchR and nAchR expression. It provides hypotheses for the positive BoNT-A effect on motor performance in hemi-PD rats based on changes in cholinergic receptor densities. The differential outcome of striatal BoNT-A application on Ach receptor densities can be interpreted as a further hint to the fact, that the densities of mAchRs and nAchRs are regulated differently by the availability of its transmitter (Sivam et al., [@B106]; Hefco et al., [@B49]). Quantification of the receptor densities of mAchRs and nAchRs provides evidence that cholinergic transmission has a significant impact on the clinical symptoms associated with DA depletion. Also other neurotransmitter receptors, especially glutamatergic and GABAergic receptors on cortical and thalamic terminals are of interest. Changes in corticostriatal glutamate release in hemi-PD rats have already been reported (Lindefors and Ungerstedt, [@B73]). To comprehensively characterize the receptor-mediated BoNT-A effect, the reaction not only of dopamine, noradrenaline, and serotonin receptors (Mann et al., [@B77]; Wedekind et al., [@B120]), but also of glutamate and GABA receptors should be investigated.
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6-OHDA

:   6-hydroxydopamine

Ach

:   acetylcholine

BoNT-A

:   botulinum neurotoxin-A

BSA

:   bovine serum albumin

CPu

:   caudate-putamen

DA

:   dopamine

DSP-4

:   N-2-chloroethyl-N-ethyl-2-bromobenzylamine

EGP

:   externus globus pallidus

hemi-PD

:   hemiparkinsonian

M~1~

:   acetylcholine muscarinic M~1~ receptor

M~2~

:   acetylcholine muscarinic M~2~ receptor

M~3~

:   acetylcholine muscarinic M~3~ receptor

MFB

:   medial forebrain bundle

MSN

:   striatal medium spiny neuron

mAchRs

:   muscarinic acetylcholine receptors

nAchRs

:   nicotinic acetylcholine receptors

PBS, phosphate-buffered saline, PD

:   Parkinson\'s disease

ROI

:   region of interest

SNpc

:   substantia nigra pars compacta

SNpr, substantia nigra pars reticulate, SNAP25

:   synaptosome-associated glycoprotein of 25-kDa.
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